Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines

Abstract

Ann Oncol 2018; 29: iv96-iv110 (doi:10.1093/annonc/mdx758) The following corrections have been made: In "Table 2. Managing anaemia in patients with MDS" In the last sentence, the word: patient has been replaced with: patients In "Table 4. Approved ESAs and i.v. iron compounds and their approved dosing in patients with solid tumours and haematological malignanciesa,b" For iron isomaltoside, maximum infusion dose, a new footnote 'e' has been added: eThe authors suggest a dose up to 1000 mg, while drug labels might allow more. For iron isomaltoside, minimum infusion time: 60 min Has been replaced with: 15 minf For iron isomaltoside, minimum infusion time, a new footnote 'f' has been added: fIf dose is up to 1000 mg; if dose exceeds 1000 mg iron, more than 30 min is recommended, as per label. In Figure 2: "Management of chemotherapy-induced anaemia in patients with very low to intermediate-risk MDS" The title has been replaced with: Management of anaemia in patients with very low to intermediate-risk MDS Under the section "Conclusions" MDS patients with low to intermediate-1 risk (IPSS) or very low to intermediate risk (revised; IPSS-R) disease and symptomatic anaemia should be considered for ESA therapy, despite the fact that ESAs are currently not EMA-approved for use in patients withMDS [I, A]. Has been replaced with: MDS patients with low to intermediate-1 risk (IPSS) or very low to intermediate risk (revised; IPSS-R) disease and symptomatic anaemia should be considered for ESA therapy, despite the fact that not all ESAs are currentlyEMA-approved for use in patients withMDS [I, A].